Immunic Future Growth
Future criteria checks 3/6
Immunic is forecast to grow earnings and revenue by 68% and 90.1% per annum respectively while EPS is expected to grow by 66.4% per annum.
Key information
68.0%
Earnings growth rate
66.4%
EPS growth rate
Biotechs earnings growth | 42.7% |
Revenue growth rate | 90.1% |
Future return on equity | n/a |
Analyst coverage | Good |
Last updated | 26 Nov 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | N/A | -99 | -87 | -87 | 6 |
12/31/2025 | N/A | -98 | -85 | -91 | 7 |
12/31/2024 | N/A | -98 | -90 | -89 | 7 |
9/30/2024 | N/A | -97 | -76 | -76 | N/A |
6/30/2024 | N/A | -95 | -73 | -72 | N/A |
3/31/2024 | N/A | -98 | -76 | -75 | N/A |
12/31/2023 | N/A | -94 | -71 | -71 | N/A |
9/30/2023 | N/A | -129 | -72 | -72 | N/A |
6/30/2023 | N/A | -127 | -68 | -68 | N/A |
3/31/2023 | N/A | -125 | -64 | -64 | N/A |
12/31/2022 | N/A | -120 | -65 | -65 | N/A |
9/30/2022 | N/A | -85 | -74 | -74 | N/A |
6/30/2022 | N/A | -83 | -78 | -78 | N/A |
3/31/2022 | N/A | -79 | -91 | -91 | N/A |
12/31/2021 | N/A | -93 | -83 | -83 | N/A |
9/30/2021 | N/A | -83 | -74 | -74 | N/A |
6/30/2021 | N/A | -77 | -68 | -68 | N/A |
3/31/2021 | N/A | -70 | -48 | -48 | N/A |
12/31/2020 | N/A | -44 | -46 | -46 | N/A |
9/30/2020 | N/A | -41 | -39 | -38 | N/A |
6/30/2020 | N/A | -36 | -33 | -32 | N/A |
3/31/2020 | N/A | -39 | -34 | -34 | N/A |
12/31/2019 | N/A | -35 | -29 | -29 | N/A |
9/30/2019 | N/A | -32 | -26 | -26 | N/A |
6/30/2019 | N/A | -26 | -22 | -22 | N/A |
3/31/2019 | N/A | -14 | -13 | -13 | N/A |
12/31/2018 | N/A | -12 | -10 | -10 | N/A |
9/30/2018 | N/A | -10 | -10 | -10 | N/A |
12/31/2017 | N/A | -10 | N/A | -10 | N/A |
12/31/2016 | 0 | -1 | N/A | -2 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 10VA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1%).
Earnings vs Market: 10VA is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 10VA is expected to become profitable in the next 3 years.
Revenue vs Market: 10VA is forecast to have no revenue next year.
High Growth Revenue: 10VA is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 10VA's Return on Equity is forecast to be high in 3 years time